NEW YORK, NY / ACCESSWIRE / October 25, 2019 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. To determine your eligibility and get free access to our shareholder support tools that provide you with case updates, automated loss calculations and claims recovery assistance, please contact the firm via the links below. There will be no cost or obligation to you.
Sarepta Therapeutics, Inc. (SRPT)
Lawsuit on behalf of: investors who purchased September 6, 2017 - August 19, 2019
Lead Plaintiff Deadline : October 29, 2019
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/sarepta-therapeutics-inc-loss-form?prid=4048&wire=1
According to the filed complaint, during the class period, Sarepta Therapeutics, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) golodirsen, Sarepta's drug for the treatment of Duchenne muscular dystrophy, posed significant safety risks to patients; (ii) consequently, the New Drug Application package for golodirsen's accelerated approval was unlikely to receive Food and Drug Administration approval; and (iii) as a result, Sarepta's public statements were materially false and misleading at all relevant times.
Meredith Corporation (MDP)
Lawsuit on behalf of: investors who purchased January 31, 2018 - September 5, 2019
Lead Plaintiff Deadline : November 5, 2019
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/meredith-corporation-loss-form?prid=4048&wire=1
According to the filed complaint, during the class period, Meredith Corporation made materially false and/or misleading statements and/or failed to disclose that: (1) the Time, Inc. acquisition was not as profitable as the Company had claimed; (2) the Company would incur additional costs for strategic investments to improve the Time business; (3) as a result, the Company's earnings would be materially and adversely impacted; and (4) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects, were materially misleading and/or lacked a reasonable basis.
The Chemours Company (CC)
Lawsuit on behalf of: investors who purchased February 16, 2017 - August 1, 2019
Lead Plaintiff Deadline : December 9, 2019
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/the-chemours-company-loss-form?prid=4048&wire=1
According to the filed complaint, during the class period, The Chemours Company made materially false and/or misleading statements and/or failed to disclose that: (1) Chemours had not appropriately accounted and accrued reserves for its environmental liabilities; (2) the possibility of costs exceeding accrued amounts was greater than the Company had represented to a point that could be material; (3) the Company's policies, standards and procedures were not properly designed to prevent unreasonable risk of harm to people and the environment (4) Chemours' handling, manufacture, use, and disposal of hazardous substances was not in accordance with applicable environmental laws and regulations; and (5) as a result of these misrepresentations, Chemours shares traded at artificially inflated prices.
You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
SOURCE: Levi & Korsinsky, LLP
View source version on accesswire.com: